447 related articles for article (PubMed ID: 33322371)
1. Prospects for NK Cell Therapy of Sarcoma.
Lachota M; Vincenti M; Winiarska M; Boye K; Zagożdżon R; Malmberg KJ
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33322371
[TBL] [Abstract][Full Text] [Related]
2. Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas.
Bareke H; Ibáñez-Navarro A; Guerra-García P; González Pérez C; Rubio-Aparicio P; Plaza López de Sabando D; Sastre-Urgelles A; Ortiz-Cruz EJ; Pérez-Martínez A
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176035
[TBL] [Abstract][Full Text] [Related]
3. Purinergic targeting enhances immunotherapy of CD73
Wang J; Lupo KB; Chambers AM; Matosevic S
J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
[TBL] [Abstract][Full Text] [Related]
4. Design and Implementation of NK Cell-Based Immunotherapy to Overcome the Solid Tumor Microenvironment.
Navin I; Lam MT; Parihar R
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33371456
[TBL] [Abstract][Full Text] [Related]
5. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
Front Immunol; 2019; 10():2683. PubMed ID: 31798595
[TBL] [Abstract][Full Text] [Related]
6. NK Cell-Based Immunotherapy in Cancer Metastasis.
Lorenzo-Herrero S; López-Soto A; Sordo-Bahamonde C; Gonzalez-Rodriguez AP; Vitale M; Gonzalez S
Cancers (Basel); 2018 Dec; 11(1):. PubMed ID: 30597841
[TBL] [Abstract][Full Text] [Related]
7. Natural killer cells: of-the-shelf cytotherapy for cancer immunosurveillance.
Zhang L; Liu M; Yang S; Wang J; Feng X; Han Z
Am J Cancer Res; 2021; 11(4):1770-1791. PubMed ID: 33948388
[TBL] [Abstract][Full Text] [Related]
8. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
9. Combining radiotherapy and NK cell-based therapies: The time has come.
Baude J; Limagne E; Ladjohounlou R; Mirjolet C
Int Rev Cell Mol Biol; 2023; 378():31-60. PubMed ID: 37438020
[TBL] [Abstract][Full Text] [Related]
10. Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors.
Quamine AE; Olsen MR; Cho MM; Capitini CM
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199783
[TBL] [Abstract][Full Text] [Related]
11. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
Hu W; Wang G; Huang D; Sui M; Xu Y
Front Immunol; 2019; 10():1205. PubMed ID: 31214177
[TBL] [Abstract][Full Text] [Related]
12. Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors.
Melaiu O; Lucarini V; Cifaldi L; Fruci D
Front Immunol; 2019; 10():3038. PubMed ID: 32038612
[TBL] [Abstract][Full Text] [Related]
13. The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer.
Rezvani K; Rouce RH
Front Immunol; 2015; 6():578. PubMed ID: 26635792
[TBL] [Abstract][Full Text] [Related]
14. Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity.
Zhang C; Oberoi P; Oelsner S; Waldmann A; Lindner A; Tonn T; Wels WS
Front Immunol; 2017; 8():533. PubMed ID: 28572802
[TBL] [Abstract][Full Text] [Related]
15. Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies.
Shang J; Hu S; Wang X
Exp Hematol Oncol; 2024 Feb; 13(1):21. PubMed ID: 38396050
[TBL] [Abstract][Full Text] [Related]
16. Natural Killer Cells as Key Players of Tumor Progression and Angiogenesis: Old and Novel Tools to Divert Their Pro-Tumor Activities into Potent Anti-Tumor Effects.
Bassani B; Baci D; Gallazzi M; Poggi A; Bruno A; Mortara L
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30939820
[No Abstract] [Full Text] [Related]
17. Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer.
Greppi M; Tabellini G; Patrizi O; Candiani S; Decensi A; Parolini S; Sivori S; Pesce S; Paleari L; Marcenaro E
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30791364
[TBL] [Abstract][Full Text] [Related]
18. Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy.
Zhang J; Zheng H; Diao Y
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646574
[TBL] [Abstract][Full Text] [Related]
19. Arrested development: suppression of NK cell function in the tumor microenvironment.
Riggan L; Shah S; O'Sullivan TE
Clin Transl Immunology; 2021; 10(1):e1238. PubMed ID: 33456775
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.
Hu Y; Tian ZG; Zhang C
Acta Pharmacol Sin; 2018 Feb; 39(2):167-176. PubMed ID: 28880014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
